No Difference in Sleep and RBD between Different Types of Patients with Multiple System Atrophy: A Pilot Video-Polysomnographical Study
Table 1
Description of the study population with valid PSGs.
Demographics
MSA-C () (29.73%)
MSA-P () (70.27%)
value
Female (%)
5 (45.45)
14 (54.55)
NS
Male (%)
6 (53.85)
12 (46.15)
NS
Age, years
67.64 ± 5.55
66.19 ± 9.17
NS
Disease duration, years
4.27 ± 2.76
3.44 ± 2.28
NS
BMI
27.28 ± 3.07
27.61 ± 4.50
NS
MMSE
26.36 ± 4.82
28 ± 1.37
NS
Signs and symptoms, (%)
Cerebellar
11 (100)
3 (11.54)
0.000
Extrapyramidal
10 (90.91)
26 (100)
NS
Pyramidal
2 (18.18)
6 (23.08)
NS
Concomitant diseases, (%)
Cardiovascular*
4 (36.36)
12 (46.15)
NS
Psychiatric**
3 (27.27)
9 (34.61)
NS
Medication
L-dopa, mg/day
391.67 ± 270.49
747.89 ± 439.50
0.017
(%)
6 (55)
19 (73)
NS
Dopamine agonists, mg/day
0
319.67 ± 299.47
NA
(%)
0
6 (23)
NA
Amantadine, mg/day
300
250 ± 100
NS
(%)
1 (9.09)
4 (15.38)
NS
SSRIs, (%)
3 (27.27)
11 (42.31)
NS
Opioids, (%)
1 (9.09)
1 (3.85)
NS
Benzodiazepines, (%)
2 (18.18)
6 (23.08)
NS
Other antipsychotics, (%)
2 (18.18)
0
NA
Values are mean ± SD, Dopamine agonists dose = L-dopa equivalent dose according to Tomlinson et al., 2010 [17], MSA-C: multiple system atrophy cerebellar predominant, MSA-P: multiple system atrophy parkinsonian predominant, BMI: body mass index, MMSE: Mini Mental State Examination, L-dopa: levodopa, SSRIs: selective serotonin reuptake inhibitors, NS: not significant ( value > 0.05), NA: not applicable.
*Clinically relevant hypertension or any other form of heart disease. **Clinically relevant psychiatric conditions.
